Mesenchymal Stem Cells Pretreatment With Stromal-Derived Factor-1 Alpha Augments Cardiac Function and Angiogenesis in Infarcted Myocardium
- 11 February 2021
- journal article
- research article
- Published by Elsevier BV in The American Journal of the Medical Sciences
- Vol. 361 (6), 765-775
- https://doi.org/10.1016/j.amjms.2021.01.025
Abstract
No abstract availableFunding Information
- Iranian Council of Stem Cell Research and Technology (F574)
This publication has 47 references indexed in Scilit:
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicineExperimental & Molecular Medicine, 2013
- VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heartCardiovascular Research, 2011
- Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells: Tips and TricksMethods in Molecular Biology, 2011
- VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN TrialMolecular Therapy, 2009
- Paracrine Mechanisms in Adult Stem Cell Signaling and TherapyCirculation Research, 2008
- Stromal Cell–Derived Factor-1α Is Cardioprotective After Myocardial InfarctionCirculation, 2008
- Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardiumJournal of Molecular and Cellular Cardiology, 2008
- CXCR4 modulates contractility in adult cardiac myocytesJournal of Molecular and Cellular Cardiology, 2006
- Vascular Endothelial Growth Factor Prevents Apoptosis and Preserves Contractile Function in Hypertrophied Infant HeartCirculation, 2006
- Vascular Endothelial Growth Factor and AngiogenesisPharmacological Reviews, 2004